HER2‐directed therapy is approved for cancers, such as unresectable or metastatic breast cancer, advanced gastric and gastroesophageal junction cancers, as well as certain colorectal cancers and HER2‐mutant lung cancers. Here, ERBB2 is linked to lung cancer.